-
公开(公告)号:US20150038402A1
公开(公告)日:2015-02-05
申请号:US14519383
申请日:2014-10-21
发明人: DAVID PAUL FAIRLIE , LIGONG LIU , MEI KWAN YAU , JACKY YUNG SUEN , ROBERT REID
CPC分类号: C07K5/0812 , A61K38/00 , C07K5/00 , C07K5/06034 , C07K5/06078 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K5/0823 , C07K5/0825
摘要: The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.
摘要翻译: 本申请提供了新的式(I)化合物,包含这些化合物的药物组合物和使用这些化合物作为生物学研究的工具的方法,或用于调节蛋白酶活化受体-2(PAR2)的药剂或药物,以及用于治疗受试者 疾病或病症的风险或易感性,或具有与不良PAR2活性相关的疾病或病症。
-
公开(公告)号:US08541628B2
公开(公告)日:2013-09-24
申请号:US10748853
申请日:2003-12-30
申请人: Carl J Wheeler
发明人: Carl J Wheeler
IPC分类号: C07C43/00 , C07C205/00 , A61K38/00 , A61K48/00 , A61K31/08 , A61K31/04 , A01N31/14 , A01N33/18 , A01N33/24
CPC分类号: C07K5/0825 , A61K9/1272 , A61K47/54 , A61K47/543 , C07C225/06 , C07C229/12 , C07C237/06 , C07C271/12 , C07C275/14 , C07C279/36 , C07C323/59 , C07K5/081
摘要: Cationic lipids having a derivatized quaternary ammonium head group that provide improved cell targeting ability and enhanced transfective efficacy for introducing molecules into cells are provided.
摘要翻译: 提供具有衍生的季铵头基的阳离子脂质,其提供改善的细胞靶向能力和增强的将细胞分子引入细胞的转染效能。
-
公开(公告)号:US20080249028A1
公开(公告)日:2008-10-09
申请号:US11885941
申请日:2006-03-08
申请人: LuGuang Luo
发明人: LuGuang Luo
CPC分类号: C07K5/0825 , A61K38/00 , C07K5/0806 , C07K5/0808 , C07K5/0821
摘要: The invention provides a method of modulating blood glucose levels by treating or preventing pancreas-related disorders with thyrotropin-releasing hormone (TRH) or a TRH derivative. Diabetes mellitus, pancreatic islet destruction, pancreatic beta cell malfunction, and hyperglycemia-related malfunction are preferably treated or prevented.
摘要翻译: 本发明提供通过用促甲状腺激素释放激素(TRH)或TRH衍生物治疗或预防胰腺相关疾病来调节血糖水平的方法。 优选治疗或预防糖尿病,胰岛破坏,胰腺β细胞功能衰竭和高血糖相关故障。
-
公开(公告)号:US20040171572A1
公开(公告)日:2004-09-02
申请号:US10748853
申请日:2003-12-30
发明人: Carl J. Wheeler
IPC分类号: A61K048/00 , A61K031/44 , A61K031/40 , A61K031/14
CPC分类号: C07K5/0825 , A61K9/1272 , A61K47/54 , A61K47/543 , C07C225/06 , C07C229/12 , C07C237/06 , C07C271/12 , C07C275/14 , C07C279/36 , C07C323/59 , C07K5/081
摘要: Cationic lipids having a derivatized quaternary ammonium head group that provide improved cell targeting ability and enhanced transfective efficacy for introducing molecules into cells are provided.
摘要翻译: 提供具有衍生的季铵头基的阳离子脂质,其提供改善的细胞靶向能力和增强的将细胞分子引入细胞的转染效能。
-
公开(公告)号:US20040014673A1
公开(公告)日:2004-01-22
申请号:US10344129
申请日:2003-05-30
IPC分类号: A61K038/06 , A61K038/05
CPC分类号: C07K5/0825 , A61K38/00 , C07K5/1024
摘要: A pharmaceutical composition for topical administration comprising an analgesic effective amount of a peptide comprising L-amino acids of the formula (I): pGLUnullXnullY-Z M (I) and a pharmaceutically acceptable excipient. X is an amino acid selected from the group consisting of GLY, VAL, GLU, ASP, SER, ALA, ASN, GLN, ILE, LEU, PRO, LYS and ARG, Y is TRP or THR, and Z is any L-amino acid, or Z is null. When Z is any L-amino acid, one but not both of Y and Z is TRP, and when Z is null, YnullTRP. An alkyl group may be attached to an amino acid of the peptide. Also disclosed are the peptide, the preparation of the pharmaceutical composition and a topical method of treating or preventing pain in a mammal.
摘要翻译: 一种用于局部给药的药物组合物,其包含镇痛有效量的包含式(I)的L-氨基酸的肽:pGLU-X-Y-Z M(I)和药学上可接受的赋形剂。 X是选自GLY,VAL,GLU,ASP,SER,ALA,ASN,GLN,ILE,LEU,PRO,LYS和ARG的氨基酸,Y是TRP或THR,Z是任何L-氨基 酸或Z为空。 当Z是任何L-氨基酸时,Y和Z之间的一个但不是二者都是TRP,当Z为零时,Y = TRP。 烷基可以连接到肽的氨基酸。 还公开了肽,药物组合物的制备和治疗或预防哺乳动物疼痛的局部方法。
-
公开(公告)号:US06319902B1
公开(公告)日:2001-11-20
申请号:US09230821
申请日:1999-05-12
申请人: Tamio Sugawara , Takayoshi Yoshikawa , Yukio Tada
发明人: Tamio Sugawara , Takayoshi Yoshikawa , Yukio Tada
IPC分类号: C07K506
CPC分类号: C07K5/06139 , A61K38/00 , C07K5/0202 , C07K5/0821 , C07K5/0825 , C07K5/1024
摘要: A peptide derivation of the formula (I) or its pharmaceutically acceptable salt or hydrate thereof is disclosed. These compounds have superior ability over thyroid stimulating hormone (TRH) and its derivatives to activate the central nervous system, such as, for example, sustained acetylcholine releasing action, anti-reserpine action and locomotor increment.
摘要翻译: 公开了式(I)的肽衍生物或其药学上可接受的盐或水合物。这些化合物具有优于促进中枢神经系统的促甲状腺激素(TRH)及其衍生物的能力,例如维持乙酰胆碱 释放作用,抗利血平作用和运动增量。
-
公开(公告)号:US5405834A
公开(公告)日:1995-04-11
申请号:US842181
申请日:1992-03-20
申请人: Hans Bundgaard , Judi Moss
发明人: Hans Bundgaard , Judi Moss
IPC分类号: A61K38/22 , A61K38/00 , A61K38/04 , A61P5/00 , A61P5/12 , C07K1/113 , C07K5/08 , C07K5/097 , C07K7/04 , A61K37/24 , A61K37/43
CPC分类号: C07K5/0825 , A61K38/00
摘要: Compounds of formula (I), wherein R.sub.1 is selected from the group consisting of an alkyl group, an aralkyl group, an alkenyl group, a cycloalkyl group, in which the alkyl, aralkyl, alkenyl or cycloalkyl group is unsubstituted or substituted with one or more substituents selected from the group consisting of a halogen atom, e.g. Cl or Br, a hydroxyl group or a straight or branched-chain alkoxy group containing from 1 to 6 carbon atoms; and the pharmaceutically acceptable acid addition salts thereof. Such compounds are prodrugs of TRH and are characterized by having a higher lipophilicity than TRH and possessing a high resistance toward degradation by TRH-inactivating enzymes. Such compounds will after administration be converted into TRH.
摘要翻译: PCT No.PCT / DK90 / 00228 Sec。 371日期:1992年3月20日 102(e)1992年3月20日PCT PCT 1990年9月3日PCT公布。 第WO91 / 03487号公报 1991年3月21日。式(I)化合物,其中R 1选自烷基,芳烷基,烯基,环烷基,其中烷基,芳烷基,烯基或环烷基 是未取代的或被一个或多个选自以下的取代基取代:卤素原子,例如, Cl或Br,含有1至6个碳原子的羟基或直链或支链烷氧基; 及其药学上可接受的酸加成盐。 这些化合物是TRH的前药,其特征在于具有比TRH更高的亲油性,并且通过TRH灭活酶具有高度降解的抗性。 给药后,这些化合物转化为TRH。
-
公开(公告)号:US5041535A
公开(公告)日:1991-08-20
申请号:US123124
申请日:1987-11-20
申请人: Olga Nyeki nee Kuprina , Istvan Schon , Lajos Kisfaludy , Laszlo Denes , Gyorgy Hajos , Laszlo Szporny , Bela Szende , Karoly Lapis
发明人: Olga Nyeki nee Kuprina , Istvan Schon , Lajos Kisfaludy , Laszlo Denes , Gyorgy Hajos , Laszlo Szporny , Bela Szende , Karoly Lapis
IPC分类号: A61K38/00 , A61P35/02 , A61P37/04 , C07K1/06 , C07K1/113 , C07K5/06 , C07K5/078 , C07K5/08 , C07K5/09 , C07K5/097 , C07K5/10 , C07K5/11 , C07K5/113
CPC分类号: C07K5/06173 , C07K5/0815 , C07K5/0825 , C07K5/1019 , C07K5/1021 , A61K38/00
摘要: The new peptides of the Formulae(1) Glp-Lys-NH.sub.2(2) Glp-Glu-Lys-NH.sub.2(3) Arg-Lys-Glu-NH.sub.2(4) Arg-lys-Asp-NH.sub.2(5) Arg-Lys-Glu-OH(6) Arg-Lys-Gln-OH(7) Leu-Val-Ala-OH(8) Arg-Orn-Asp-Val-NH.sub.2(9) Arg-Orn-Asp-Val-OH(10) Lys-Glu-Lys-Lys-OH(11) Lys-Leu-Lys-Lys-OH(12) Lys-Asp-Leu-Lys-OH(13) Glu-Leu-Val-Ala-OH and(14) Leu-Pro-Ala-Gly-OHand acid addition salts thereof inhibit the proliferation of leukaemic cells and exhibit immunostimulant effect.
摘要翻译: 式(1)的新肽Glp-Lys-NH2(2)Glp-Glu-Lys-NH2(3)Arg-Lys-Glu-NH2(4)Arg-lys-Asp-NH2(5)Arg-Lys -Glu-OH(6)Arg-Lys-Gln-OH(7)Leu-Val-Ala-OH(8)Arg-Orn-Asp-Val-NH2(9)Arg-Orn-Asp-Val-OH )Lys-Glu-Lys-Lys-OH(11)Lys-Leu-Lys-Lys-OH(12)Lys-Asp-Leu-Lys-OH(13)Glu-Leu-Val-Ala-OH和(14) Leu-Pro-Ala-Gly-OH及其酸加成盐抑制白血病细胞的增殖并显示出免疫刺激作用。
-
公开(公告)号:US4328134A
公开(公告)日:1982-05-04
申请号:US147112
申请日:1980-05-06
申请人: Andrew V. Schally , David H. Coy
发明人: Andrew V. Schally , David H. Coy
CPC分类号: C07K5/0825
摘要: There are disclosed peptides of the formula A-B-C and pharmaceutically acceptable salts thereof, in which A is selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, and L-homo-pyroglutamyl; B is selected from the group consisting of L-histidyl, L-3'-methylhistidyl, D-histidyl, L-phenylalanyl, L-p-aminophenylalanyl, and L-.beta.-(pyrazolyl-1)alanyl; and C is selected from the group consisting of glycine and lower alkyl esters thereof, glycinamide and lower alkyl amides thereof, 2-amino-1-hydroxyethyl, D-alanine, L-.beta.-(2-thienyl)-alanine, and NHR.sup.1 in which R.sup.1 is lower alkyl, with the proviso that C may not be glycine or glycinamide when A is L-pyroglutamyl and B is L-histidyl.The compounds have anorexigenic properties, inhibit excessive gastric and pancreatic secretion, and cause activation in the CNS. Methods for their preparation and use are also disclosed.
摘要翻译: 公开了式A-B-C的肽及其药学上可接受的盐,其中A选自L-焦谷氨酰基,D-焦谷氨酰和L-高 - 焦谷氨酰; B选自L-组氨酰基,L-3'-甲基组氨酸,D-组氨酰基,L-苯丙氨酰基,L-对氨基苯丙氨酰和L-β-(吡唑基-1)丙氨酰基; 和C选自甘氨酸及其低级烷基酯,甘氨酰胺及其低级烷基酰胺,2-氨基-1-羟乙基,D-丙氨酸,L-β-(2-噻吩基) - 丙氨酸和NHR1 其中R1为低级烷基,条件是当A为L-焦谷氨酰基且B为L-组氨酰基时,C不为甘氨酸或甘氨酰胺。 这些化合物具有厌食性,抑制胃和胰腺分泌过多,并引起CNS中的活化。 还公开了其制备和使用方法。
-
公开(公告)号:US4305872A
公开(公告)日:1981-12-15
申请号:US086417
申请日:1979-10-19
CPC分类号: C07K5/0825 , C07K14/702 , C07K7/23 , A61K38/00 , Y10S930/13 , Y10S930/16 , Y10S930/26
摘要: Compounds comprising polypeptide derivatives of the formula ##STR1## wherein R.sub.1 is the amino acid sequence of the polypeptide minus the terminal amino acid; R is the side chain group determining the identity of the terminal amino acid; and Z is ##STR2## or --CH.sub.2 X wherein X is Cl, Br, or I; are provided. Precursor peptides are peptide hypothalamic releasing and inhibitory factors, opiate peptides, and fragments thereof. The derivatives act as antagonists or agonists to the precursor peptides and are particularly useful in bioassay procedures.
摘要翻译: 包含式IMAGE的多肽衍生物的化合物,其中R1是多肽的氨基酸序列减去末端氨基酸; R是确定末端氨基酸同一性的侧链基团; 或Z为
或-CH 2 X,其中X为Cl,Br或I; 被提供。 前体肽是肽下丘脑释放和抑制因子,鸦片肽及其片段。 衍生物作为前体肽的拮抗剂或激动剂,并且在生物测定程序中特别有用。
-
-
-
-
-
-
-
-
-